

Oxervate

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:		Date:
Patient's ID:		Patient's Date of Birth:
Physician's Name:		
Specialty:		NPI#:
Physician Office Telephone:		Physician Office Fax:
Referring Provider Info: ☐ Same as Re	equesting Provi	der
Name:		NPI#:
Fax:		Phone:
Rendering Provider Info: Same as Rendering	_	
Name:		
Fax:		Phone:
		s in accordance with FDA-approved labeling, vidence-based practice guidelines.
Patient Weight:	kg	
Patient Height:	cm	
Please indicate the place of service for the	e requested drug	:
\square Ambulatory Surgical	\square Home	Off Campus Outpatient Hospital
On Campus Outpatient Hospital	□ Office	☐ Pharmacy

Clinical Criteria Questions: What is the ICD-10 code?	
 1. What is the diagnosis? ☐ Neurotrophic keratitis (If checked, go to 2) ☐ Other, please specify. (If checked, go to 2) 	
 2. What is the severity of the neurotrophic keratitis? ☐ Stage 1 (If checked, no further questions) ☐ Stage 2 (If checked, go to 3) ☐ Stage 3 (If checked, go to 3) ☐ Other (If checked, no further questions) 	
3. Did the patient experience persistent epithelial defects (PED) or corn refractory to one or more conventional non-surgical treatments (e.g., pr ☐ Yes, <i>Continue to 4</i> ☐ No, <i>Continue to 4</i>	
4. Does the patient have evidence of decreased corneal sensitivity (e.g., contact aesthesiometer, CRCERT-Belmonte non-contact aesthesiometer ulcer and outside of the area of the defect in at least one corneal quadra ☐ Yes, <i>Continue to 5</i> ☐ No, <i>Continue to 5</i>	er) within the area of the PED or corneal
 5. Has the patient ever received Oxervate previously? ☐ Yes, Continue to 6 ☐ No, No Further Questions 	
6. Has the patient received a previous 8 week course of Oxervate in the ☐ Yes, <i>Continue to 7</i> ☐ No, <i>Continue to 7</i>	affected eye?
 7. Is the patient currently receiving Oxervate in the affected eye? ☐ Yes, Continue to 8 ☐ No, Continue to 8 	
8. How many weeks of Oxervate therapy has the patient received for th In-Between Numbers: 7.9999 and 9999.0 (If checked, <i>no further que</i> Outside In-Between Numbers: 7.9999 and 9999.0 (If checked, <i>no further que</i>	estions)
I attest that this information is accurate and true, and that documentat	
information is available for review if requested by CVS Caremark or the	
Prescriber or Authorized Signature	Date (mm/dd/yy)

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Oxervate SGM – 02/2023.